Abstract
BackgroundMatrix metallopeptidase 14 (MMP14) is an important gene in the regulation of T-cell function. However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.MethodsWe investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). The expression of MMP14 was analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA). The correlation between MMP14 and immune cell infiltration was investigated using the Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) and Tumor Immune Estimation Resource (TIMER) tools. In addition, the correlation between MMP14 expression and immune gene markers was analyzed by TIMER and GEPIA.ResultsMMP14 expression positively correlated with favorable progression-free survival (PFS; GSE98588, P = 0.02) and overall survival (OS; GSE98588, P = 0.003; GSE10846, P = 5.517e-05; and GSE4475, P = 9.85e-04). Moreover, MMP14 expression was higher in DLBCL tumors than in normal tissues. Regarding clinical characteristics, high MMP14 expression was found to be correlated with race. MMP14 expression was also correlated with immune cell infiltration and had a remarkable correlation with various immune marker sets. It was found that M0 macrophages were the immune cells most related to survival, decreasing with the increase in Ann Arbor clinical stage. The results especially showed that MMP14 was a prognostic biomarker and related to the macrophages M0.ConclusionThe results suggest that MMP14 is a novel prognostic molecular marker for DLBCL and is related to the immune cell infiltration, especially related to the macrophages M0. Our study provides insights for understanding the potential roles of MMP14 in tumor immunology and its suitability as a prognosis biomarker in DLBCL.
Highlights
Diffuse large B-cell lymphoma (DLBCL) is the clinically and genetically heterogeneous group comprising malignant proliferations of large lymphoid B cells, according to the definition by the World Health Organization (WHO) classification [1, 2]
These genes significantly correlated with Overall survival analyses (OS) based on the median gene expression values (Figure 1A)
Gene Expression Profiling Interactive Analysis uncovered that the Matrix metallopeptidase 14 (MMP14) expression was higher in DLBCL tumors than in normal tissues (Figure 2A)
Summary
Diffuse large B-cell lymphoma (DLBCL) is the clinically and genetically heterogeneous group comprising malignant proliferations of large lymphoid B cells, according to the definition by the World Health Organization (WHO) classification [1, 2]. There is an urgent need to identify novel potential prognostic biomarkers and to investigate the mechanisms of immune involvement in tumorigenesis and tumor progression in the context of DLBCL. Enhancing the immune response against the tumor could benefit patients affected with DLBCL, improving their survival [12, 13]. The role of MMP14 in the clinical prognosis and immune cell infiltration in DLBCL remains unclear. We investigate potential new prognostic markers for DLBCL using a bioinformatics approach with data already available in public datasets. Matrix metallopeptidase 14 (MMP14) is an important gene in the regulation of T-cell function. The correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
